Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The collaboration will leverage PostEra's AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen's drug discovery expertise, to advance up to 5 small molecule programs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2023
Lead Product(s) : Antiviral Therapeutic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : National Institutes of Health
Deal Size : $68.0 million
Deal Type : Funding
Details : ASAP will use PostEra's end-to-end AI-first approach to accelerate the discovery process, generating molecules with optimised properties, designing rapid synthesis, and optimally prioritising experiments.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 18, 2022
Lead Product(s) : Antiviral Therapeutic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : National Institutes of Health
Deal Size : $68.0 million
Deal Type : Funding
Lead Product(s) : Antiviral Therapeutic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Breyer Capital
Deal Size : $24.0 million
Deal Type : Series A Financing
PostEra Closes $24M in New Financing to Advance Drug Discovery
Details : PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Antiviral Therapeutic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Breyer Capital
Deal Size : $24.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?